Morgan Stanley analyst Erin Wright lowered the firm’s price target on Envista (NVST) to $16 from $19 and keeps an Equal Weight rating on the shares. While policy will be “front and center” with varying degrees of exposure, or lack there of, across the Healthcare Services and Technology space, the focus will also be on indications of underlying utilization trends across MCOs, distributors, providers, labs, animal and dental into Q1, the analyst tells investors in a preview for the group.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVST:
- Envista price target lowered to $21 from $23 at UBS
- Envista price target lowered to $19 from $21 at Wells Fargo
- Positive Outlook for Envista Holdings: Strategic Growth and Strong Brand Drive Buy Rating
- Envista Holdings: Balancing Growth Potential and Management Challenges Amidst Market Recovery
- Envista Holdings: Strategic Focus and Market Outlook Justify Hold Rating